Upendra K. Marathi
Director Ejecutivo en 7 Hills Pharma LLC .
Perfil
Upendra K.
Marathi is the founder of 7 Hills Pharma LLC.
Prior to founding 7 Hills Pharma LLC, he worked as a Managing Director at MediGen Group LLC, a Senior Vice President at PLx Pharma, Inc., a Principal at BCM Technologies, Inc., and a Faculty Member at Rice University.
He holds an MBA from Rice University and a doctorate from Loyola University of Chicago.
Cargos activos de Upendra K. Marathi
| Empresas | Cargo | Inicio |
|---|---|---|
7 Hills Pharma LLC
 7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Director Ejecutivo | - |
Antiguos cargos conocidos de Upendra K. Marathi.
| Empresas | Cargo | Fin |
|---|---|---|
BCM Technologies, Inc.
 BCM Technologies, Inc. Investment ManagersFinance BCM Technologies Inc (BCM Technologies) is a venture capital subsidiary of Baylor University founded in 1983. The firm is headquartered in Houston, Texas. | Corporate Officer/Principal | - |
PLx Pharma, Inc. /Old/
 PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Corporate Officer/Principal | - |
| Rice University | Corporate Officer/Principal | - |
MediGen Group LLC
 MediGen Group LLC Investment ManagersFinance Founded in 2001 by Ronald Zimmerman, MediGen Group LLC is a venture capital firm located in Houston, Texas | Inversor de Capital Privado | - |
Formación de Upendra K. Marathi.
| Rice University | Masters Business Admin |
| Loyola University of Chicago | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 4 |
|---|---|
PLx Pharma, Inc. /Old/
PLx Pharma, Inc. /Old/ Pharmaceuticals: OtherHealth Technology PLx Pharma, Inc. engages in the development of formulations of non steroidal anti-inflammatory drugs. Its products include GI-safer NSAID technology and product pipeline; aspirin, ibuprofen and indomethacin as well as other drugs for over-the-counter and prescription markets using the PLxGuard technology. The company was founded in 2003 and is headquartered in Houston, TX. | Health Technology |
BCM Technologies, Inc.
BCM Technologies, Inc. Investment ManagersFinance BCM Technologies Inc (BCM Technologies) is a venture capital subsidiary of Baylor University founded in 1983. The firm is headquartered in Houston, Texas. | Finance |
MediGen Group LLC
MediGen Group LLC Investment ManagersFinance Founded in 2001 by Ronald Zimmerman, MediGen Group LLC is a venture capital firm located in Houston, Texas | Finance |
7 Hills Pharma LLC
7 Hills Pharma LLC Pharmaceuticals: MajorHealth Technology 7 Hills Pharma LLC is a clinical-stage pharmaceutical company based in Houston, TX. The private company is developing first-in-concept integrin activators to augment immunotherapies for the treatment of drug-resistant solid tumors and infectious diseases. The lead compound, 7HP349, is an oral VLA-4/LFA-1 allosteric activator that will be in phase I testing for PD-1 refractory solid tumors and geriatric influenza. The company's compounds are expected to augment antigen presentation and immune priming to facilitate a productive immune response against a variety of antigens. 7 Hills Pharma is managed by an experienced group of pharmaceutical executives, including Richard A. F. Dixon, Upendra K. Marathi, Kala Marathi, Peter Vanderslice, and Darren Woodside. Upendra K. Marathi has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Upendra K. Marathi
